sebra / Shutterstock.com
Sandoz has brought to market its generic pregabalin product with a full label in the UK and a skinny label in France. Varuni Paranavitane of Osborne Clarke reports on court rulings in the UK, and most recently France, on actions brought by Warner-Lambert against Sandoz.
Since the early 1980s, the European Patent Office has granted second medical use patents for new uses of known pharmaceutical products. Second medical use patents can cover a new indication, a new dosage regimen, or a new method of treatment. For example, Aspirin, possibly the world’s most commonly used drug, was first discovered for its analgesic properties; only subsequently were its anticoagulant properties discovered. The interpretation of second medical use claims, and consequently the approach to infringement of these claims by courts, varies from jurisdiction to jurisdiction and is a developing area of the law.
Warner-Lambert’s European patentnumber EP 0 934 016, covering the use of pregabalin for the treatment of pain, has been the subject of a multitude of patent disputes across Europe. Courts have to balance the patentee’s rights to exclude competitors from entering the market for its patent-protected indication against the legitimate rights of the generics companies to enter the market for all other indications which are not patent-protected.
One way in which generics companies seek to avoid infringement is by obtaining a marketing authorisation for all indications except the patent-protected indication (so-called skinny labelling). This article considers two recent actions brought by Warner-Lambert against Sandoz’s pregabalin in England and France.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at email@example.com.
If you have any technical issues please email tech support.
Varuni Paranavitane, Osborne Clarke, Lyrica, Warner-Lambert, Sandoz, Pregabalin product, generics, patent,